Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.
礼来（纽交所：LLY）、诺和诺德（纽交所：NVO）、viking therapeutics（纳斯达克：VKTX）和结构疗法公司（纳斯达克：GPCR）的股票周三交投走低。
What happened? Earlier on Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity.
发生了什么？周三早些时候，罗氏控股AG（场外交易：RHHBY）宣布了Ct-996治疗2型糖尿病和肥胖症一项正在进行中的多部分第一期临床试验的两个分支的头部结果。
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
数据显示，Ct-996在没有2型糖尿病的肥胖病人中治疗4周后，平均体重损失较安慰剂组减少了6.1%，属于临床意义上的。
This data is better compared to existing competitors.
与现有竞争对手相比，这些数据更好。
Also Read: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO.
还阅读：独家：Tema etf CEO预测GLP-1减重药市场可能成为万亿市场。
In March, Viking Therapeutics released results from the company's Phase 1 multiple ascending dose trial of an oral tablet formulation of VK2735 in development for metabolic disorders such as obesity.
3月份，viking therapeutics公布了该公司VK2735口服片剂的一项一期多剂量试验的结果，该试验正在开发用于代谢性疾病如肥胖症。
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline of up to 5.3%, and relative to placebo, ranging up to 3.3%.
接受VK2735的队列显示出基线平均体重的剂量依赖性降低，最高可达5.3％，且相对于安慰剂范围高达3.3％。
In a study published on the JAMA Internal Medicine website, Eli Lilly's Mounjaro users experienced a mean loss in body weight of 5.9% at three months, compared to 3.6% for Novo Nordisk's Ozempic users.
在JAMA内科网站上发表的一项研究中，礼来的Mounjaro用户在三个月内的平均体重减轻了5.9％，而诺和诺德的Ozempic用户减轻了3.6％。
At six months, the mean loss was 10.1% for Mounjaro users versus 5.8% for Ozempic users. At 12 months, the mean body weight loss for Mounjaro users was 15.3% and 8.3% for Ozempic users.
到了六个月时，Mounjaro用户的平均减肥量为10.1％，而Ozempic用户为5.8％。到12个月时，Mounjaro用户的平均体重减轻量为15.3％，而Ozempic用户为8.3％。
In June, Structure Therapeutics Inc. (NASDAQ:GPCR) unveiled 12-week topline obesity data from its Phase 2a study of GSBR-1290, demonstrating a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.
6月份，GPCR公布了GSBR-1290临床研究的12周头部肥胖数据，显示12周内体重平均减轻了6.2％，存在临床意义和统计学意义上显著的安慰剂调整。
At Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss, and 33% achieved ≥ 10% weight loss, compared to 0% for placebo.
在第12周，GSBR-1290组中有67%的参与者达到≥6%体重减轻目标，33%的人达到了≥10%的体重减轻目标，而安慰剂组为0%。
Price Action: At last check Wednesday, LLY stock was down 3.00% at $913.37, NVO shares were down 4.15% at $135.02, GPCR stock was down 16.01% at $37.50, and VKTX shares were down 11.10% at $50.70.
股票走势：截至周三最后一次检查，LLY股票下跌3.00％至913.37美元，NVO股票下跌4.15％至135.02美元，GPCR股票下跌16.01％至37.50美元，VKTX股票下跌11.10％至50.70美元。
- Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.
- 一项研究显示，仅有25%的患者在使用诺和诺德的Wegovy或Ozempic 2年后仍坚持使用；公司称数据不足。
Photo by Vidmir Rais via Pixabay
来自Pixabay的Vidmir Rais摄影作品